Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Cerrado

2.34 -2.5

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.38

Máximo

2.41

Métricas clave
By Trading Economics
Ingresos	663K -7M
Ventas	426K 2.6M
P/B Media del Sector	6.324 57.002
BPA	-0.07
Margen de beneficios	-269.254
Empleados	75
EBITDA	665K -7M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+107.47% upside

Dividendos
By Acuity
Próximas Ganancias	9 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-3.8M 221M
Apertura anterior	4.84
Cierre anterior	2.34

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 ago 2026, 23:51 UTC

Cryptocurrency Declines Reflect Broader Investor Caution Amid Economic Uncertainties and Geopolitical Tensions.

16 ago 2026, 23:51 UTC

Japan's GDP growth data highlights economic recovery amid global caution, while U.S. retail sales drop raises concerns over interest rate hikes and geopolitical tensions impact financial stability.

16 ago 2026, 23:51 UTC

Cryptocurrency and major indices decline amid economic uncertainties, with Bridgewater warning of "crunch time" for capital expenditures and consumer sentiment dropping sharply.

16 ago 2026, 23:51 UTC

Bitcoin and Ethereum decline as major indices show mixed performance amid cautious market sentiment and concerns over capital expenditures.

16 ago 2026, 23:51 UTC

NAHB Housing Market Index for August 2026 set to release with forecast of 33.0 amid cautious sentiment and declining builder confidence.

16 ago 2026, 23:51 UTC

Correlated Moves

Macro News

Bitcoin is lower at $63,022 amid broader market pressures from mixed cryptocurrency movements and recent economic data showing declining U.S. retail sales.

16 ago 2026, 23:41 UTC

Japan's GDP Growth Preliminary Release Expected to Show Modest +0.02% Year-over-Year Increase Amid Mixed Regional Economic Sentiment

16 ago 2026, 23:41 UTC

Japan's Q2 GDP Growth Rate Expected at 0.5% Amid Cautious Market Sentiment and Rising Oil Prices

16 ago 2026, 23:41 UTC

China's July Retail Sales YoY data set for August 17, 2026, forecasts a rise to 1.5%, signaling cautious optimism amid mixed economic indicators.

16 ago 2026, 23:41 UTC

China's Industrial Production YoY data for July 2026 set to release with a forecasted growth rate of 5.0%, amid cautious market sentiment and concerns over declining fixed asset investment.

16 ago 2026, 23:41 UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.5% in June Amid Mixed Economic Sentiment

16 ago 2026, 23:41 UTC

China's Fixed Asset Investment Expected to Decline by 6.2% YoY, Raising Concerns Over Economic Growth

16 ago 2026, 23:31 UTC

U.S. Industrial Production MoM data for July 2026 set to release on August 18, with cautious optimism amid mixed signals and a forecasted increase of 0.3%.

16 ago 2026, 23:21 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Cautious Optimism and Mixed Economic Signals on August 20, 2026.

16 ago 2026, 23:21 UTC

Canada's New Housing Price Index set for release amid cautious optimism and government infrastructure investments aimed at stabilizing home prices.

16 ago 2026, 23:11 UTC

China's House Price Index YoY release on August 17, 2026, may reveal ongoing pressures in the housing market amid cautious economic indicators and mixed global market performance.

16 ago 2026, 23:02 UTC

Correlated Moves

USD/SEK is lower during after-market hours, continuing a downward trend since Friday. Broader market dynamics are influencing the currency pair's movement.

16 ago 2026, 23:01 UTC

CAD/JPY shows a modest increase in after-hours trading, maintaining an upward trajectory since Friday's close amid a generally positive trading context.

16 ago 2026, 23:01 UTC

Macro News

The US 30Y Treasury Bond Index is trading lower as mixed China economic data raises concerns about global growth prospects. It pulled back from earlier session highs.

16 ago 2026, 23:01 UTC

The US 10Y Treasury Bond Index is lower today, trading down from Friday's close. The index remains in the middle of its one-month range.

16 ago 2026, 23:01 UTC

The CAD/CHF currency pair is higher in after-market hours, reflecting notable strength and unusual activity. It is positioned above its 20-day moving average.

16 ago 2026, 23:01 UTC

GBP/CHF is trading higher during after-market hours, maintaining a steady upward movement since Friday's close. The asset remains near the upper end of its one-month range.

16 ago 2026, 23:01 UTC

Gold and silver are trading higher during Sunday’s session, gaining ground since Friday's close. Key economic data from China is expected tomorrow.

16 ago 2026, 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and maintaining a position above its 20-day moving average.

16 ago 2026, 23:01 UTC

Correlated Moves

Gold/SGD is higher today, reflecting a modest increase since Friday's close. The asset remains above its 20-day moving average amid rising silver prices.

16 ago 2026, 23:01 UTC

Correlated Moves

Gold/JPY is trading higher, reflecting a slight increase since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

16 ago 2026, 23:01 UTC

Correlated Moves

Gold/HKD is advancing during the session, reflecting a broader trend as silver also gains. The asset remains above its 20-day moving average.

16 ago 2026, 23:01 UTC

Correlated Moves

Gold/GBP is trading higher, reflecting a modest advance since Friday's close. The asset remains above its 20-day moving average and near recent highs.

16 ago 2026, 23:01 UTC

Correlated Moves

Silver/JPY is higher today, supported by a rise in gold and anticipation of key economic data from China.

16 ago 2026, 23:01 UTC

Correlated Moves

Silver/SGD is rising in the current session, supported by a broader trend in precious metals, with gold also gaining.

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

107.47% repunte

Estimación a 12 Meses

Media 5 USD 107.47%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.